- Home
- MGEE vs NAMS Comparison
MGEE vs NAMS Comparison
Compare MGEE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGEE | NAMS |
|---|---|---|
| Founded | 1855 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGEE | NAMS |
|---|---|---|
| Price | $81.00 | $27.68 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $80.50 | $46.75 |
| AVG Volume (30 Days) | 163.6K | ★ 981.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 11.71 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.02 | $17.96 |
| Revenue Next Year | $2.77 | $540.65 |
| P/E Ratio | $61.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $72.16 | $23.05 |
| 52 Week High | $88.01 | $42.21 |
Technical Indicators
Market Signals| Indicator | MGEE | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 36.81 |
| Support Level | $80.63 | N/A |
| Resistance Level | $82.70 | $37.29 |
| Average True Range (ATR) | 1.75 | 1.64 |
| MACD | -0.29 | -0.28 |
| Stochastic Oscillator | 48.80 | 28.03 |
Price Performance
Historical ComparisonAbout MGEE MGE Energy Inc
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.